Actively Recruiting
Safety and Dose Evaluation of FC084CSA Tablets Combined with Tislelizumab in Treating Advanced Malignant Solid Tumors
Led by FindCure Biosciences (ZhongShan) Co., Ltd. · Updated on 2026-09-04
33
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, and effectiveness of the drug FC084CSA combined with Tislelizumab in patients who have advanced malignant solid tumors. This clinical trial includes adults aged 18 to 75 who have either failed standard therapy for solid tumors or have specific stages of non-small cell lung cancer NSCLC where surgery or radiotherapy is not an option. The study is divided into two phases to carefully assess dosing and initial treatment responses. The first phase Phase Ib uses a dose escalation method called 33 to gradually increase the dose of FC084CSA alongside a fixed dose of Tislelizumab, monitoring closely for any dose-limiting toxicities. Once a recommended Phase 2 Dose RP2D is identified, the second phase Phase IIa expands the patient group to further assess the safety and early effectiveness of this dose combination, with a focus on NSCLC patients. Treatment continues until specific toxicities occur or until the dose level is deemed suitable. Participants will undergo regular assessments including measurement of tumor response according to RECIST 1.1 criteria, monitoring for side effects, and pharmacokinetic testing over several months. The primary outcomes include determining the maximum tolerated dose, recommended dose, dose-limiting toxicities, and objective response rate. Secondary outcomes track disease control rate, progression-free survival, overall survival, and detailed pharmacokinetic parameters. The total study duration spans up to about 18 months for survival follow-up.
CONDITIONS
Brief Title
A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
Research Team
T
Tingjin Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here